Streptococcus pneumoniae News and Research

RSS

Streptococcus pneumoniae, or Pneumococcus, is a very common bacterial infection in both industrialized and developing countries. In particular, young children and the elderly represent high-risk populations of developing pneumococcal infections. According to the WHO, the bacterium kills up to one million children under the age of five years each year worldwide. It accounts for many Bacterial Meningitis cases in adults and it is the most common cause of Bacteraemia, Pneumonia, Meningitis and Otitis media in young children.

FDA approves new indication for Wyeth's Tygacil (tigecycline)

Wyeth Pharmaceuticals, a division of Wyeth has announced that the U.S. Food and Drug Administration (FDA) approved Tygacil (tigecycline), for the treatment of adult patients with community-acquired bacterial pneumonia (CABP) caused by susceptible strains of indicated pathogens.

24 Mar 2009

Wyeth's Prevenar vaccine for pneumococcal disease registered in Russia

Wyeth announced today that its 7-valent pneumococcal conjugate vaccine, Prevenar (Pneumococcal saccharide conjugated vaccine, Adsorbed), has been registered by the Russian Ministry of Health and Social Development (Roszdravnadzor) and is expected to be commercially available later this year.

2 Mar 2009

Bacteria-killing enzyme cures mice with fatal pneumonia

Before the advent of antibiotics, pneumonia claimed so many lives - and was so feared - that it was called the "captain of the ship of death."

1 Mar 2009

Super-fine oil-and-water emulsion protects against superbugs that kill cystic fibrosis patients

University of Michigan scientists report highly encouraging evidence that a super-fine oil-and-water emulsion, already shown to kill many other microbes, may be able to quell the ravaging, often drug-resistant infections that cause nearly all cystic fibrosis deaths.

5 Feb 2009

Pediatric vaccine propels sharp drop in meningitis cases

A pediatric vaccine with University of Rochester roots has proven to be highly successful at reducing cases of bacterial meningitis across all age groups.That is the conclusion of a seven-year study, the results of which appeared today in the New England Journal of Medicine.

14 Jan 2009

Adults with asthma at increased risk of serious pneumococcal disease

Mayo Clinic research shows adults with asthma are at increased risk of serious pneumococcal disease caused by Streptococcus pneumoniae, the most common bacteria causing middle ear infections and community acquired pneumonia.

22 Dec 2008

Research suggests that immunity is stronger at night

The immune system's battle against invading bacteria reaches its peak activity at night and is lowest during the day.

14 Dec 2008

New vaccines may not reduce tuberculosis incidence

Despite the potential of new vaccines to prevent TB, new research shows that the removal of one strain of TB can allow a previously suppressed strain to succeed. Consequently, a vaccination program could result in the proliferation of strains more likely to be, or become, drug resistant, and could even result in an increased prevalence of the disease.

6 Oct 2008

Advanced Life Sciences submits NDA for cethromycin in mild-to-moderate community acquired pneumonia

Advanced Life Sciences Holdings, Inc. has announced the submission of a new drug application (NDA) for cethromycin in mild-to-moderate community acquired pneumonia (CAP). Advanced Life Sciences also entered into debt and equity financing agreements to strengthen its balance sheet and help fund commitments associated with the NDA submission and pre-commercialization activities.

2 Oct 2008

Bacteriophages treat deadly bacterial infections in mice

By the time antibiotics made their clinical debut 70 years ago, bacteria had long evolved strategies to shield themselves. For billions of years, bacteria hurled toxic molecules at each other in the struggle to prosper, and those that withstood the chemical onslaught marched on.

2 Jul 2008

Despite vaccine, public should not get complacent about pneumococcal disease

Although the childhood pneumococcal conjugate vaccine has been a boon in reducing the incidence invasive pneumococcal disease (IPD), the public and the medical community must not get complacent, as non-vaccine strains, some resistant to antibiotics, are on the rise, say scientists at a meeting today in Boston.

3 Jun 2008

Ashwell receptor plays key role in reducing coagulation abnormalities during infection and sepsis

In research that solves the longest-standing mystery in glycobiology - a field that studies complex sugar chains called glycans - researchers at the University of California, San Diego School of Medicine have discovered that a molecule in the liver of all animals, called the Ashwell receptor, is critical in helping the body fight off the abnormal and lethal blood clotting caused by bacterial infection.

19 May 2008

Corticosteroids not linked with reduced risk of death for children with bacterial meningitis

Use of corticosteroids in addition to other treatment for children with bacterial meningitis is not associated with a decreased risk of death or shorter hospital stay, according to a study in the May 7 issue of JAMA, the Journal of the American Medical Association.

6 May 2008

Pneumococcal disease rates down since approval of a vaccine in 2000

Since the approval of a vaccine against pneumococcal bacteria for young children in 2000, rates of invasive pneumococcal disease (IPD) are down significantly in all age groups, while rates of IPD caused by non-vaccine strains are modestly on the rise.

19 Mar 2008

Research could put penicillin back in battle against antibiotic resistant bugs

Research led by the University of Warwick has uncovered exactly how the bacterium Streptococcus pneumoniae has become resistant to the antibiotic penicillin.

13 Mar 2008

Purified bacterial extract sprayed into lungs ramps up innate immune system

A purified extract prepared from a common microbe and delivered to the lungs of laboratory mice in a spray set off a healthy immune response and provided powerful protection against all four major classes of pathogens including those responsible for anthrax and bubonic plague, according to a presentation at the American Society for Cell Biology's 47th Annual Meeting.

4 Dec 2007

Vaccinating children younger than age 2 with the pneumococcal vaccine linked to less hospitalizations

Vaccinating children younger than age 2 with the pneumococcal vaccine appears to be associated with decreased hospitalizations from pneumonia and reduced health care expenses, according to a report in the December issue of Archives of Pediatrics & Adolescent Medicine.

4 Dec 2007

Pneumococcal conjugate vaccines can improve the lives of HIV-infected children

An international team of experts has published the first comprehensive review of evidence on pneumococcal conjugate vaccination (PCV) for children with HIV infection.

29 Nov 2007

Uptake of pneumococcal conjugate vaccine among children in the 1998-2002 United States birth cohorts

Since its addition to the list of routine immunizations in 2000, one childhood vaccine has helped prevent some pneumococcal-related illness, including pneumonia and otitis media.

27 Nov 2007

number of cases of most vaccine-preventable diseases is at an all-time low

A comparison of illness and death rates for 13 vaccine-preventable diseases in the U.S., before and after use of the vaccine, indicates there have been significant decreases in the number of cases, hospitalizations and deaths for each of the diseases examined, according to a study in the November 14 issue of JAMA: The Journal of the American Medical Association.

14 Nov 2007